Background: Tumor-derived circulating cell-free DNA (cfDNA) is present in the plasma of individuals with cancer. Assays aimed at detecting common cancer mutations in cfDNA are being developed for the detection of several cancer types. In breast cancer, however, such assays have failed to detect the disease at a sensitivity relevant for clinical use, in part due to the absence of multiple common mutations that can be co-detected in plasma. Unlike individual mutations that exist only in a subset of tumors, unique DNA methylation patterns are universally present in cells of a common type and therefore may be ideal biomarkers. Here we describe the detection and quantification of breast-derived cfDNA using a breast-specific DNA methylation signature. Patients and methods: We collected plasma from patients with localized breast cancer before and throughout treatment with neoadjuvant chemotherapy and surgery (N ¼ 235 samples). Results: Pretreatment breast cfDNA was detected in patients with localized disease with a sensitivity of 80% at 97% specificity. High breast cfDNA levels were associated with aggressive molecular tumor profiles and metabolic activity of the disease. During neoadjuvant chemotherapy, breast cfDNA levels decreased dramatically. Importantly, the presence of breast cfDNA towards the end of the chemotherapy regimen reflected the existence of residual disease. Conclusion: We propose that breast-specific cfDNA is a universal and powerful marker for the detection and monitoring of breast cancer.
INTRODUCTION
Early detection of breast cancer, before metastatic spread, is key to a cure.
Mammography-based screening provides an estimated 20% reduction in breast cancer mortality rates 1 but has drawbacks including a high false-positive rate, limited sensitivity, and patient discomfort. 2 Tools to detect breast cancer also have important applications in monitoring treatment response and detecting disease relapse. Serial imaging often fails to detect tumor burden, while circulating protein biomarkers such as cancer antigen 15-3 (CA 15-3) suffer from a lack of sensitivity and long half-life in circulation, 3 reducing the ability to track short-term changes in treatment response.
Monitoring of treatment response is particularly important in the context of neoadjuvant (preoperative) chemotherapy (NACT), offered to some patients diagnosed with localized breast cancer. The reduction in tumor burden in response to neoadjuvant therapy translates to significantly higher survival rates. 4 The current standard of care mandates surgery following NACT, even in the presence of radiological complete response, although it is possible that omission of surgery is safe in some cases. 5 Nevertheless, patients not achieving complete tumor regression following standard NACT are candidates for additional therapy. Therefore, there is a need for improved tools to detect residual disease.
Cell-free DNA (cfDNA) molecules circulating in the blood are emerging as important non-invasive biomarkers for monitoring physiological and pathological processes, including cancer. Healthy individuals have low concentrations (w1000 genome equivalents/ml plasma) of cfDNA, with higher concentrations in pathologies including cancer. 6 As cfDNA is short-lived in circulation 7 it is an ideal biomarker for monitoring dynamic processes.
Circulating tumor DNA (ctDNA), identified based on the presence of somatic mutations, can provide information on the presence of cancer and its genetic composition 8 and is correlated with clinical parameters such as stage, disease burden, recurrence, and response to treatment. 9e12 However, in breast cancer, ctDNA analysis has a low sensitivity of detection (<40%), 13 in part due to the low frequency of common mutations in breast cancer. 14 DNA methylation patterns are retained in the cfDNA molecules of their tissue of origin. DNA methylation, occurring at cytosine residues followed by a guanine nucleotide (CpG sites), is conserved among cells of the same type across individuals and in health and disease conditions. 15 We and others have shown that an analysis of cfDNA methylation can reveal its tissue of origin, serving as a potential biomarker for pathologies involving cell death and hence, cfDNA release from a specific tissue. 16e18 In the context of breast cancer, some studies have attempted to utilize aberrant methylation of specific tumor-suppressor genes as a cfDNA biomarker 19e21 with variable success. We have adopted an alternative approach, relying on genomic loci with a methylation pattern unique to breast epithelium (normal and cancerous) compared with other tissues. Such loci can serve as highly specific, yet universal, markers for breast DNA. We hypothesized that healthy women have minimal breast cfDNA and that elevated concentrations of breast cfDNA could imply a pathological process such as breast cancer.
Here we describe a DNA methylation-based assay capable of detecting circulating breast DNA in a specific and sensitive manner and provide a preliminary proof of concept for its use in breast cancer detection.
PATIENTS AND METHODS

Subjects and study design
The trial was approved by the Hadassah Institutional Review Board and all patients gave written informed consent. Subjects were eligible if they had biopsy-proven breast cancer and were referred to NACT by their treating oncologist. Between January 2017 and February 2018, 53 women were screened during standard preoperative evaluation. All women underwent breast ultrasound, breast MRI, staging PET/CT imaging, and biopsy of breast and axilla (when required); 34 consented to serial blood tests but one was found to have metastatic disease on PET imaging and therefore was not a candidate for NACT. Of the remaining 33 individuals, 30 had blood drawn before treatment, while 29 had blood drawn while undergoing a neoadjuvant chemotherapy regimen. We prospectively collected blood for cfDNA analysis at baseline and every cycle of chemotherapy. The women had the opportunity to forego blood testing so most patients did not have blood samples from all potentially available time points. The NACT regimens were determined according to the treating physician's decision. All women were operated on after completion of NACT and tumor assessment was done by a certified pathologist. Patient information was obtained, with consent, from pathology and imaging reports associated with patients' files. The fraction of breast DNA molecules in a sample was defined as the average fraction of molecules containing the breast-unique DNA methylation pattern across the three markers. To obtain absolute levels of breast cfDNA (genome equivalents/ml), we multiplied the fraction of breast-derived molecules by the concentration of cfDNA present in the sample (see supplementary methods, available at Annals of Oncology online).
RESULTS
Markers of breast-derived DNA
In order to identify genomic regions with unique methylation patterns in breast epithelium, we compared genome-wide methylation profiles of normal breast tissue and breast cancer to genome-wide methylation profiles of other normal and cancerous tissues and identified CpG sites with breast-unique methylation patterns ( Figure 1A ; supplementary Figures S1e S4 and Table S1 , available at Annals of Oncology online). We interrogated the selected regions, including the originally identified CpG and adjacent CpGs, taking advantage of the tissue specificity of methylation haplotype blocks 16 by massively parallel sequencing of bisulfite converted DNA ( Figure 1B ) (supplementary Table S2 , available at Annals of Oncology online). By quantifying the proportion of molecules in a sample that harbored breast-specific methylation patterns, we obtained an estimate of the proportion of the sample derived from breast epithelial cells. In breast and breast cancer tissue, 14%e46% of molecules contained the breast signature, while in the fluorescence-activated cell sorter (FACS)-sorted breast epithelial cells, an even higher fraction of molecules contained the breast signature (>75%); in all other tissues analyzed, the breast signal was minimal ( Figure 1C ). In order to determine the accuracy and sensitivity of the assay, we mixed breast DNA with leukocyte DNA in different proportions (0%, 0.1%, 1%, 10%, 100%) with a total of 20 ng DNA (approximately 6000 genome equivalents) and quantified the amount of breast DNA in each sample. Breast DNA was detected in proportions as low as 0.1% (approximately six genome equivalents) and with a high accuracy (Pearson's r > 0.99, P < 10e-5 for all markers) ( Figure 1D ).
Breast DNA circulation in healthy women and patients with metastatic disease
We analyzed the plasma of patients with metastatic disease (n ¼ 17) as well as healthy women (n ¼ 64). All three markers distinguished between the plasma of healthy donors and patients with metastatic disease (P < 10e-5 for all). No breast molecules were detected in the plasma of most healthy controls ( Figure 2A ) and breast cfDNA levels in healthy women were not elevated at any point during their menstrual cycle (supplementary Figure S5 , available at Annals of Oncology online). Using the average signal of all markers to estimate the amount of breast genome equivalents per milliliter of plasma, cancer patients could be separated from healthy donors with high sensitivity and specificity [Receiver operating characteristic (ROC) area under the curve (AUC) ¼ 90.44% (95% confidence interval 78.51%e100%)] (Figure 2B,C) .
Breast DNA in the circulation of patients with localized disease
After discovering that breast DNA could be detected in the circulation of patients with metastatic breast cancer, we tested plasma samples from patients with localized disease (stage IIAeIIIC) before, throughout, and after neoadjuvant chemotherapy. Before treatment, patients [n ¼ 30, average age 49 (32e89), detailed in supplementary Tables S3eS4, available at Annals of Oncology online] had significantly higher levels of circulating breast DNA as compared with healthy donors [n ¼ 64, average age 38 (18e83)] [P ¼ 5.3e-12; ROC AUC 91.25% (83.79%e98.71%)], with an average of 33.5 breast genome equivalents/ml (GE/ml), compared with 0.5 GE/ml observed in healthy donors ( Figure 3A ). Overall, breast cancer patients could be identified with a sensitivity of 80% while maintaining a specificity of 97%. Importantly, the use of all three breast DNA markers had increased sensitivity compared with any single marker alone, which had sensitivities of 60% (krt19), 40% (lmx1b), and 63% (znf296) at a specificity of 97% ( Figure 3B ). Assuming a cutoff corresponding to two standard deviations greater than the average breast cfDNA levels found in healthy controls (2.787 GE/ml), 73% of patients were found to be positive for breast cfDNA (see supplementary Table S5 , available at Annals of Oncology online, for a detailed comparison of positive/negative patients). The markers of breast epithelial DNA were confirmed to be present in the primary tumors but not in peripheral blood cells of the patients involved in the study (all n ¼ 13 analyzed) (supplementary Figure S6 , available at Annals of Oncology online), indicating that a lack of a signal in plasma reflects low levels of DNA release from the tumor rather than the absence of a marker in tumor tissue. Total cfDNA concentration alone could not reliably discriminate between patients and healthy individuals (supplementary Figure S7 available at Annals of Oncology online).
Interestingly, the level of breast cfDNA before treatment was associated with the molecular profile of the underlying tumor (P ¼ 0.05, KruskaleWallis test), as patients with HER2þ/ERÀ tumors had higher levels of breast cfDNA than other patients (P ¼ 0.02) (Table 1, Figure 3C , and supplementary Figure S8 , available at Annals of Oncology online). Patients with HER2þ/ERÀ and HER2À/ERÀ tumors could be distinguished from controls with relative ease (ROC AUC 99.6% and 99.7%, respectively) compared with patients with HER2þ/ERþ or HER2À/ERþ tumors (ROC AUC 85.5% and 81.1%, respectively) (supplementary Figure S9 , available at Annals of Oncology online). Of the three immunohistochemical marks, lack of progesterone receptor expression was most notably associated with breast cfDNA followed by negative staining for the estrogen receptor. HER2 expression was not associated with breast cfDNA levels (Table 1, Figure 3D ). Breast cfDNA was positively associated with tumor burden in axillary lymph nodes (Pearson's r ¼ 0.49, P < 0.05) as well as metabolic activity in axillary lymph nodes as measured by 18fluorodeoxyglucose positron emission tomographycomputed tomography (PET-CT) (Spearman's rho ¼ 0.63, P < 0.05) ( Table 1 and supplementary Figure S10 , available at Annals of Oncology online). In contrast, levels of baseline breast cfDNA were not associated with cancer stage (P ¼ 0.79, KruskaleWallis test) ( Figure 3E ), tumor size in breast or fraction of proliferating cells ( Table 1 and supplementary Figures S11 and S12, available at Annals of Oncology online).
We collected plasma from patients (n ¼ 29, detailed in supplementary Tables S3 and S4, available at Annals of Oncology online) at multiple time points throughout treatment (average of seven samples per patient, total of 207 samples) (supplementary Figure S13 , available at Annals of Oncology online). In the first measurement after the onset of neoadjuvant chemotherapy (2e4 weeks), patients already demonstrated a dramatic reduction of breast cfDNA, which on average was maintained throughout treatment. The lowest levels of breast cfDNA were observed shortly after surgery, at which point they were not significantly different from healthy donors ( Figure 4A ). Importantly, patients who had residual disease at the time of surgery demonstrated elevated levels of breast cfDNA late into treatment (during the fifth month of treatment) ( Figure 4B,D) . Additionally, levels of breast cfDNA during the last month of neoadjuvant treatment could predict the presence of residual disease (P ¼ 0.006) ( Figure 4C ) and were significantly lower than at the start of treatment for patients with a complete response to treatment but not for patients with residual disease (P ¼ 0.008 and P ¼ 0.58, respectively, Wilcoxon signed-rank test) (supplementary Figure S14 , available at Annals of Oncology online). The association between breast cfDNA and residual disease is strong even when taking into account other factors such as age, receptor status, and stage (supplementary Table S6 , available at Annals of Oncology online).
DISCUSSION
We describe a DNA methylation-based epigenetic signature of breast DNA, which can be used as a universal biomarker for breast-derived cfDNA. We found that breast cfDNA levels are elevated in breast cancer and reflect tumor biology. Furthermore, we found that breast cfDNA decreases in response to chemotherapy and is reflective of the Figure 1 ) and localized breast cancer patients (n ¼ 30). Cancer patients had significantly elevated concentrations of breast cfDNA (P ¼ 5.3e-11, ManneWhitney U test). An offset of 1 was added to all samples for plotting in the log scale. (B) The ROC curve for identifying breast cancer patients. The concentration of breast cfDNA was defined using an average of the three markers (black line) or the three markers independently (colored lines). AUC for the black line: 91.25% (83.79%e98.71%). (C) The concentration of breast cfDNA measured as above, with samples separated by their receptor status at initial biopsy. The red dotted line denotes the upper limit of the norm (mean of controls þ two standard deviations). An offset of 1 was added to all samples for plotting in log scale. The level of breast cfDNA pretreatment was associated with the molecular profile of the underlying tumor (P ¼ 0.05, KruskaleWallis test). Specifically, patients with ERÀ/HER2þ tumors had significantly more breast DNA in plasma presence of residual disease towards the end of the treatment protocol.
We evaluated the relevance of our approach for earlystage breast cancer, focusing on patients with localized disease who received neoadjuvant chemotherapy. Before treatment, many of these patients had elevated levels of breast cfDNA. This suggests a potential utility of the approach for early detection of breast cancer. Our findings provide several insights into the determinants of detectable breast cfDNA. First, the combined use of three independent breast DNA markers increased the sensitivity of breast cancer detection. This suggests that a further increase in the number of markers tested on the same sample could increase sensitivity. Notably, hundreds of universally conserved breast methylation markers can be identified and potentially co-detected, underscoring the potential utility of methylation patterns as an ultrasensitive biomarker. Second, breast cfDNA was associated with specific aspects of tumor biology (lack of hormone receptor expression, size, and metabolic activity of tumor in axillary lymph nodes) and was not associated with other features such as breast tumor size and measurements of proliferation. This supports a view of tumor cfDNA as a reflection of specific biological processes rather than just a constitutive marker of tumor mass, consistent with analysis of mutant DNA in the plasma of breast cancer patients 22 and contrasting with previous reports on association between mutant tumor DNA and proliferation or tumor size in other cancer types. 10, 23, 24 The onset of neoadjuvant chemotherapy was associated with a decrease in levels of breast cfDNA. In some cases, breast cfDNA was elevated until the time of surgery, indicative of continued tumor growth and turnover despite treatment that is consistent with residual disease observed in the pathology of such patients. Importantly, high breast cfDNA concentration in the weeks leading up to surgery predicted residual disease at the time of surgery. These data suggest that breast cfDNA could be a useful biomarker for cancer recurrence after apparently successful treatment. Further studies may be designed to test this possibility more concretely. Due to the limitations of this study, such as size and duration (only two patients were deceased at the writing of this manuscript), breast cfDNA levels could not be evaluated as a prognostic indicator for survival and this possibility should be evaluated in further studies.
In summary, in this preliminary study, we provide proof of the concept that breast cfDNA quantification opens a window into the dynamics of breast cancer with a potential for early diagnosis, monitoring of treatment response, and detection of recurrence. It should be noted that this study is based on data obtained from a small number of individuals who underwent neoadjuvant chemotherapy and further validation in another series of patients receiving neoadjuvant chemotherapy is necessary. Additionally, further expansion of the panel of breast DNA markers used may dramatically increase assay sensitivity and clinical utility. We also underscore the importance of sufficiently powered studies to explain the variance in breast cfDNA concentrations seen among patients and to test the utility of breast cfDNA in identifying recurrence of the disease. Finally, while in this study we have focused on patients with localized disease at stage IIeIII, future studies, using a maximally sensitive version of the assay, should examine the relevance of this approach to patients at even earlier stages of the disease. (P ¼ 0.017). (D) Boxplots of breast cfDNA concentrations in plasma shown for patients with ER-negative tumors versus ER-positive tumors, PR-negative tumors versus PR-positive tumors, and HER2-negative tumors versus HER2-positive tumors. Patients with ER-negative tumors or PR-negative tumors had significantly more breast DNA in circulation (P ¼ 0.02 for ER-negative, P ¼ 0.003 for PR-negative). HER2 status was not associated with breast cfDNA (P ¼ 0.65). The red dotted line denotes the upper limit of the norm (mean of controls þ 2 standard deviations). An offset of one was added to all samples for plotting on a log scale. E. The concentration of breast cfDNA separated by stage of the disease. The red dotted line denotes the upper limit of the norm (mean of controls þ 2 standard deviations). An offset of 1 was added to all samples for plotting on a log scale. There was no significant difference between the groups (P ¼ 0.79, KruskaleWallis test). Before initiation of treatment, breast cfDNA levels were elevated but then dropped upon initiation of treatment. Subsequently, breast cfDNA levels increased gradually through three serial measurements, which correlated with a clinically detected increase in tumor mass as well as residual disease at surgery. After surgery, breast cfDNA levels decreased to zero; however, several months after surgery levels increased above baseline, anticipating a subsequent detection of metastatic recurrence by imaging.
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